Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)  
$88.63 1.44 (1.6%) as of 4:30 Fri 4/19


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 188,370,000
Market Cap: 16.70(B)
Last Volume: 1,778,607 Avg Vol: 1,398,026
52 Week Range: $76.22 - $99
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  811
Guru Rank Value     : 0.9
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 3,625
Total Buy Value $0 $0 $0 $314,469
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 139,229 182,993 316,353 594,697
Total Sell Value $12,316,080 $16,513,389 $28,948,007 $56,737,885
Total People Sold 5 5 6 7
Total Sell Transactions 11 15 24 53
End Date 2024-02-04 2023-11-03 2023-05-05 2022-05-05

   
Records found: 1213
  Page 18 of 49  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2012-05-01 4 AS $35.00 $699,920 D/D (20,000) 113,191     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2012-05-01 4 OE $9.86 $197,200 D/D 20,000 133,191     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2012-05-01 4 AS $34.99 $174,950 D/D (5,000) 30,018     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2012-05-01 4 OE $11.05 $55,250 D/D 5,000 35,018     -
   Cooper Jeffrey H SVP, Chief Financial Officer   •       –      –    2012-04-30 4 A $19.35 $19,056 D/D 985 41,089     -
   Aselage Steve EVP, Chief Business Officer   •       –      –    2012-04-30 4 A $19.35 $19,462 D/D 1,006 47,685     -
   Wood Mark VP, Human Resources   •       –      –    2012-04-30 4 A $27.91 $13,395 D/D 480 21,114     -
   Davis George Eric SVP, General Counsel   •       –      –    2012-04-30 4 A $19.35 $18,959 D/D 980 40,631     -
   Baffi Robert EVP, Technical Operations   •       –      –    2012-04-30 4 A $19.35 $17,798 D/D 920 84,413     -
   Mueller Brian VP, Corporate Controller   •       –      –    2012-04-30 4 A $19.35 $12,846 D/D 664 8,964     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2012-04-30 4 A $19.35 $21,242 D/D 1,098 113,191     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2012-04-30 4 A $19.35 $21,242 D/D 1,098 30,018     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2012-04-27 4 AS $34.66 $769,872 D/D (22,000) 112,093     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2012-04-27 4 OE $9.86 $197,200 D/D 20,000 134,093     -
   Wood Mark VP, Human Resources   •       –      –    2012-04-23 4 AS $34.54 $64,006 D/D (1,853) 20,634     -
   Wood Mark VP, Human Resources   •       –      –    2012-04-23 4 OE $14.39 $32,884 D/D 1,853 22,487     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2012-04-20 4 AS $35.00 $269,185 D/D (7,691) 28,920     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2012-04-02 4 AS $34.08 $170,380 D/D (5,000) 36,611     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2012-04-02 4 OE $11.05 $55,250 D/D 5,000 41,611     -
   Wood Mark VP, Human Resources   •       –      –    2012-03-22 4 AS $35.65 $66,139 D/D (1,855) 20,634     -
   Wood Mark VP, Human Resources   •       –      –    2012-03-22 4 OE $14.39 $32,916 D/D 1,855 22,489     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2012-03-09 4 S $34.46 $516,867 D/D (15,000) 114,093     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2012-03-09 4 OE $6.47 $97,050 D/D 15,000 129,093     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2012-03-08 4 S $35.00 $35,000 D/D (1,000) 114,093     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2012-02-29 4 S $36.26 $36,258 D/D (1,000) 115,093     -
  1213 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 18 of 49
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us